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Background: DNA methylation is a well-known epigenetic mechanism involved in epigenetic gene regulation.
Several genes were reported hypermethylated in CRC, althought no gene marker was proven to be individually of
sufficient sensitivity or specificity in routine clinical practice. Here, we identified novel epigenetic markers and
assessed their combined use for diagnostic accuracy.
Methods: We used methylation arrays on samples from several effluents to characterize methylation profiles in CRC
samples and controls, as established by colonoscopy and pathology findings, and selected two differentially
methylated candidate epigenetic genes (NPY, PENK). To this gene panel we added WIF, on the basis of being
reported in literature as silenced by promoter hypermethylation in several cancers, including CRC. We measured
their methylation degrees by quantitative multiplex-methylation specific PCR (QM-MSP) on 15 paired carcinomas
and adjacent non-cancerous colorectal tissues and we subsequently performed a clinical validation on two different
series of 266 serums, subdivided in 32 CRC, 26 polyps, 47 other cancers and 161 with normal colonoscopy. We
assessed the results by receiver operating characteristic curve (ROC), using cumulative methylation index (CMI) as
variable threshold.
Results: We obtained CRC detection on tissues with both sensitivity and specificity of 100%. On serum CRC
samples, we obtained sensitivity/specificity values of, e.g., 87%/80%, 78%/90% and 59%/95%, and negative
predictive value/positive predictive value figures of 97%/47%, 95%/61% and 92%/70%. On serum samples from
other cancers we obtained sensitivity/specificity of, e.g, 89%/25%, 43%/80% and 28%/91%.
Conclusions: We showed the potential of NPY, PENK, and WIF1 as combined epigenetic markers for CRC diagnosis,
both in tissue and serum and tested their use as serum biomarkers in other cancers. We optimized a QM-MSP for
simultaneously quantifying their methylation levels. Our assay can be an effective blood test for patients where CRC
risk is present but difficult to assess (e.g. mild symptoms with no CRC family history) and who would therefore not
necessarily choose to go for further examination. This panel of markers, if validated, can also be a cost effective
screening tool for the detection of asymptomatic cancer patients for colonoscopy.
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Table 1 Patients characteristics of clinical studies
Characteristic Patients Controls















Mean ± SD 67.9 ± 12.9 59.1 ± 16.5
Range 36-94 18-94
Stage
I/II 6 (2/4) Na
III/IV 26 (7/19) Na
*In total 30 tisue samples corresponding to 15 CRC and 15 normal
homologous tissues from 15 CRC patients were analyzed.
Na: not applicable.
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Colorectal cancer (CRC) is one of the most frequent
malignant diseases worldwide [1,2] yielding high rate
mortality [3]. Early diagnosis of CRC is required to
increase the survival rates of patients [4]. Currently,
endoscopic examination of the colon is the standard for
CRC diagnosis. However, this procedure is invasive, un-
pleasant, carries a number of associated risks of morbidity
and mortality and is inaccurate for screening purposes in
the average risk populations [5]. Fecal tests (e.g. occult
blood test-FOBT and Fecal altered DNA tests) seeking
to detect presence of colorectal tumors are available as
a pre-colonoscopy test [6-9]. Although FOBTs can sig-
nificantly reduce mortality due to CRCs [10,11], these
tests are flawed by higher rates of false-negatives and
false-positives as referred to colonoscopy [12]. In this
context, new specific CRC markers for diagnosis of CRC
are needed. Over the last decade, aberrant methylation of
CpG islands in the promoter and exon 1 regions of tumor
suppressor genes is common mechanism in human
cancers [13-15] and suggested that measurement of the
methylation level can aid diagnosis [16-18].
In the present study, we propose a panel of tumor-
specific methylation genes (NPY, PENK, and WIF1) which
in combination show a potential as epigenetic markers for
the colorectal cancer diagnosis. We have developed a quan-
titative multiplex-methylation specific PCR (QM-MSP)
to quantitate cumulative methylation of these markers in
tissue and serum samples. On serum sample, we suggest
that our QM-MSP can help in preselecting the patients
having mild symptoms or without CRC family history for




Human samples were collected from individuals referred
to the gastrointestinal endoscopy units of several academic
hospitals (Table 1). Patients gave informed consent (regis-
tered under 04–2004 and revised as CPP-IDF IX-11-019 by
CPP, consultative ethical committee in the Ile de France-Est
medical district), blood samples were collected prior to
colonoscopy. Endoscopy and pathology reports were
recorded on anonymized files. Tumor biopsies were ob-
tained under colonoscopy procedures or by using surgical
resections. Tissue samples have been frozen at −80°C until
DNA was extracted. For each individual, samples were also
paraffin-embedded and conserved for pathology analyses.
In all cases, samples of normal homologous colonic tissues
were similarly conserved. They were used for microsatellite
instability analysis and the KRAS mutations which are rou-
tinely performed in our hospital before undergoing methy-
lation testing and tumor staging was determined according
to the TNM-classification (Additional file 1: Table S1).Description of the clinical study
First, a comprehensive DNA methylation profiling was
performed on DNA from 30 tissues, stools and serum
samples using Illumina goldengate methylation arrays that
contain 1,505 markers (CpG loci) within 807 cancer-related
genes (Illumina, CA). We selected NPY, PENK on the basis
of their hypermethylation and their power to discriminative
normal from CRC patients. Secondly, these candidate
genes, together with WIF1gene that we selected based
on evidence from literature [19-31], were evaluated in a
multiplex assay on an additional 15 normal/cancer paired
colonic tissues. Thirdly, validations of the multiplex assay
were carried out on the two independent series of sera
(Table 2). Series 1 contained 49 serum samples including
9 patients with CRC, 10 patients with large polyp aden-
omatous (1 cm in diameter or more) at colonoscopy
with 30 individuals with normal colonoscopy. Series 2
validation was carried out on 170 serum samples from
23 patients presenting with CRC, 16 patients with large
polyp adenomatous, and 131 control individuals with
tumor-free at colonoscopy (Figure 1). In the Series 3, we
assayed 47 patients suffering from a digestive or extra
digestive tumor other than CRC such as breast, prostate,
kidney, bladder, liver, esophagus, pancreas, cholangiocarci-
noma and stomach cancers.
Table 2 Clinicopathologic characteristics in serum
samples of patients with CRC and healthy control
Characteristic CRC Polyps Controls
Series 1 n = 9 n = 10 n = 30
Sex
Male 3 6 15
Female 6 4 15
Age
Mean ± SD 66.1 ± 17.2 71.5 ± 11.8 62. 1 ± 17.3
Range 36-94 56-91 22-91
Stage
I/II 4 (1/3) Na Na
III/IV 5 (1/4) Na Na
Series 2 n = 23 n = 16 n = 131
Sex
Male 18 10 71
Female 5 6 60
Age
Mean ± SD 68.6 ± 11.2 61.8 ± 9.2 58.5 ± 16.3
Range 51-84 52-85 18-94
Stage
I/II 2 (1/1) Na Na
III/IV 21 (6/15) Na Na
Series 1 + 2 pooled n = 32 n =26 n = 161
Sex
Male 21 16 86
Female 11 10 75
Age
Mean ± SD 67.9 ± 12.9 65.5 ± 11.1 59.1 ± 16.5
Range 36-94 52-91 18-94
Stage
I/II 6 (2/4) Na Na
III/IV 26 (7/19) Na Na
Na: not applicable.
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Figure 1 Schematic representation of the study design. First
target genes have been identified by using Illumina microarray
analyses on tissues, stools, sera. Then a multiplex methylated test
has been constructed and evaluated on tissue samples. Finally, two
validations in sera have been then performed (Series 1 and 2).
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DNA was isolated from colonic tissues and stool samples
by using a QIAamp DNA Mini Kit (Qiagen), and a
QiAamp DNA stool mini kit (Qiagen), respectively. DNAs
were isolated by using a ZR Serum DNA kit (Zymo
Research) according to the manufacturer’s protocol and
were stored at −20°C until methylation quantification after
concentrations were performed using the Eppendorf Bio-
Photometer. Bisulfite treatment was adopted to transform
unmethylated cytosine nucleotides into thymidine without
changing methylated cytosines. This was carried out
after DNA was chemically modified with sodium bisulfite
at 50°C in the dark for 16 hours by using an EZ DNA
Methylation kit (Zymo Research).Quantitative methylation-specific PCR amplification
Modified DNA was analyzed by QS-MSP (quantitative
singleplex-methylation specific PCR), and the QM-MSP
(quantitative multiplex-methylation specific PCR). All PCR
reactions were performed using an ABI prism 7900 HT
sequence detector (Applied Biosystems). For each PCR
run, a master-mix was prepared, primers and probes for
WIF1, NPY and PENK have been designed, and a primer/
probe set of albumin not containing CpG sites was used
for normalizing the DNA amounts (Additional file 2:
Table S2). The thermal cycling conditions included an
initial denaturizing step at 95°C 48 cycles for 15 s and at
60°C for 1 min. Bisulfite methylated DNA (Zymo Research)
was used as calibrator and positive control. DNA free
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level of methylation was determined by the 2-ΔΔCt method
as described in supplementary data and the efficiency of
reactions was determined by plotting in logarithmic scale
the amounts of methylated DNA versus the corresponding
Cts (cycle threshold) as baseline curves of the genes.
Bisulfite genomic sequencing
The PCR products of albumin, NPY, PENK, and WIF1
genes were purified before submission to the sequencing
process of both strands by using BigDye Terminator Cycle
Sequencing kit (Applied Biosystems) according to the
manufacturer’s instructions. The sequence reactions were
run and analyzed on an ABI 3100 Genetic Analyzer
(Applied Biosystems).
DNA methylation profiling using Illumina Goldengate
methylation bead arrays
500 ng of bisulfite-converted DNA were probed on the
Illumina Goldengate Methylation Cancer Panel I. A total
of 30 DNA samples were assayed on the Illumina platform.
Totally, there were seven tissue samples (3 colon cancer
tissue, 1 large polyp tissue and 3 paired adjacent normal
tissues), 20 stools samples (7 CRC patients, 3 individuals
with large polyp adenomatous and 10 individuals with
normal colonoscopy), and three pools of their serum DNA
samples including colon cancer patients, patients with
polyp adenomatous and individuals with normal colon-
oscopy. The values for each CpG site as a value in the
range of 0 –100.0% of methylation after subtracting
background of negative controls on the array and taking
the ratio of the methylated signal intensity to the sum of
both methylated and unmethylated signals were provided
by Illumina together with a technical p-value.
Data analysis
1) Selection of biomarker candidates on the microarray
data: we first flagged the features on the array that did not
pass the quality score recommended by the manufacturer;
the number of non-flagged was higher in tissues (1300 to
1400) than in serum (1200 to 1400) or stools (1000 to
1200). Hierarchical clustering analysis revealed a striking
difference in methylation between specimens taken from
normal colonoscopy individuals and those from cancer
patients, for both tissues and effluent samples. To investi-
gate the results at the simple locus level, we proceeded
as follows: we computed the averages of each locus’
methylation values across all samples for tissue and
stool in each category of normal (N) and cancer (Ca)
individuals; for blood, we retained the value provided by
Illumina for the single pooled sample assayed. Differences
(Ca-N) between cancer and normal tissues or milieus were
computed and the results were ranked according to Ca-N.
Then for each of tissue, serum and stool we selected themost differentially methylated loci by taking the top decile
in the Ca-N ranked differences. We performed cross com-
parisons between the three lists so obtained by intersecting
those lists. We found 5 CpG loci in the three-wise inter-
section, above the number expected (p_val 0.019).
2) Performance for CRC discrimination of combined
NPY/PENK/WIF1: we computed a cumulative methylation
index (CMI) consisting in the sum of the three methylation
values for each sample and used it as a varying threshold
for constructing a ROC curve. Specificity is calculated as
the number of true negatives divided by the number of true
negatives plus false positives. Sensitivity is calculated as the
number of the true positives divided by the number of true
positives plus false negatives. NPV is calculated as the
number of the true negatives divides by the number of true
negatives plus false negatives. PPV is calculated as the
number of the true positives divided by the number of true
positives plus false positives.
Results
Selection of candidate biomarkers by DNA methylation-array
To screen for candidate biomarkers, we carried out a
microarray study on tissue, serum and stool samples.
We found 5 CpG loci, distributed among 4 genes in the
intersection of the most differentially methylated loci; we
selected PENK and NPY in that gene set (Additional
file 3: Figure S1). We brought those two genes, together
with WIF, into a QM-MSP assay for evaluation and clinical
validation.
Verification of DNA promoter methylation status
by bisulfite sequencing
Both methylated and unmethylated alleles were identified
and fully characterized in a series of 12 PCR products
through a bi-directional sequencing process and specific
forward and reverse primers that did not contain CpG
sites (Additional file 2: Table S2). As illustrated for WIF1
marker, sequencing results revealed that all CpG covering
the amplicon in tumor samples were uniformly methylated.
By contrast, in adjacent normal tissues all CpG were
uniformly unmethylated showing the presence of thymidine
nucleotides instead of cytosine on CpG sites, which
suggests that bisulfite induced conversion (Additional
file 4: Figure S2).
Efficiency and specificity of the real-time QM-MSP assay
We evaluated the performance of two different PCR-based
assays, quantitative singleplex-MSP (QS-MSP) and quanti-
tative multiplex-MSP (QM-MSP), in order to quantify
the methylation levels of NPY, PENK, and WIF1. For
co-amplifying two methylation-specific DNA targets
in real-time, we used the associations of Fam/Vic
and Ned/Vic fluorophore probes as each probe pre-
sents a strong individual spectral intensities with limited
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and QM-MSP to determine which assay agreed best with
the detection thresholds (Ct) on a serial dilution experi-
ment from 10 ng to 10 pg of methylated DNA. Both QS-
MSP and QM-MSP gave similar cycle threshold (Ct) values
for each dilution point (data not shown) with similar high
amplification efficiency (Figure 2A, 2B).
QM-MSP assays in paired normal and tumor tissues
We used two multiplex assays, namely Alb-Fam/WIF1-Vic
and the NPY-Ned/PENK-Vic, to measure methylation
of our three biomarkers in a set of 15 paired normal
and tumor tissue samples. We set thresholds for the
levels of methylation of, respectively, 25% for NPY, 17%
for PENK, and 7% for WIF1 and obtained the following
corresponding performances: NPY displayed 100% sensi-
tivity (Se) and 100% specificity (Sp), PENK displayed 80%/
93.3%, and WIF1 displayed 73.3%/93.3%, respectively
(Additional file 5: Table S3). The sum of all methylation
values across the three genes or cumulative methylation
index (CMI), ranged between 2% and 58% in adjacent
normal tissues and was greater or equal to 99% in carcin-
oma tissues (Figure 3A). The mean values (±SD) of CMI in
adjacent normal tissues (15.07 ± 16.60) were significantly

























Figure 2 Efficiency of quantitative simplex (QS) and multiplex (QM) m
methods, namely A: quantitative multiplex methylation-specific PCR (QM-MSP
reactions have been performed in duplicate. We used a mixture of primers an
of Albumin, WIF1, PENK, and NPY genes along with a titration of human geno
On each dilution, the cycle threshold (Ct) was determined for standard DNA.
performance over 3 logs. The slope of −3.32 (100% efficiency) reflects a 2-fold
correlation coefficient R2 of 0.99 shows a high degree of linearity over the entp < 0.0001, Student-test; Figure 3). With a CMI threshold
of 58%, a Se of 100% (15 of 15) and a Sp of 100% (15 of 15)
were obtained (Additional file 5: Table S3) and no signifi-
cant differences of CMI related to the stages of carcinoma
could be observed according to TNM staging: 156.74 ±
83.96 for stages I/II and 213.14 ± 68.66 for stages III/IV
(P = 0.09, Student-test; Figure 3B).
Validation of QM-MSP test in the sera for the detection
of CRC
We measured NPY, PENK and WIF1 by QM-MSP on two
hundred and sixty six serum samples and assayed the
discrimination power of their CMI. The set of samples
consisted in a preliminary clinical set (Series 1) that included
49 individuals (30 presenting with normal colonoscopy, 10
with large adenomatous polyps and 9 with CRC) and in
a second clinical set (Series 2) including 170 individuals
(131 presenting with normal colonoscopy, 23 with CRC,
16 with large polyp adenomatous) (Table 2).
CMI values were used for calculating the Specificity
(Sp) versus the Sensitivity (Se) depending on various
thresholds and the ROC (Receiver Operating Characteris-
tic) diagrams were constructed. For each of the two series,
we obtained similar ROC profiles for CRC detection
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) and B: quantitative singleplex methylation-specific PCR (QS-MSP). The
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NPY 151  12 68      1 99      1 109    1 79      1 63      6 151    9 124    2 139    1 71     25 93      2 72      2 116  15 127    4 98      6 100
PENK 71 11 26 1 10 1 63 2 21 0 31 14 74 17 43 3 79 2 7       31 30      1 27      2 3      10 27      0 53    12 100
WIF1 135    3 32      0 0        0 142    2 79      1 59      9 0       7 65      0 39     0 25       2 3        0 0        0 69      3 69      0 16      1 100
Total 357  26 126    2 109    2 314    5 179    2 153  29 225  33 232    5 257    3 103   58 126    3 99      4 188  28 223    4 167 19 300
Figure 3 Cumulative promoter hypermethylation of WIF1, PENK, and NPY in adjacent normal and colorectal carcinoma tissues. A,
cumulative methylation levels in tumor tissues and homologous adjacent normal tissues in an independent experiment, paired samples (n = 15)
of adjacent normal and tumor tissue were quantified by using QM-MSP. Samples were scored for cumulative methylation index (CMI) of three
genes. Results are plotted as stacked bar graphs. Differences of CMI between homologous adjacent normal tissues (Norm) versus tumor tissues
(Tumor) were significant (P < 0.0001, Student-test). Plotted is the mean (± SD; bars) amount of CMI in Norm (mean = 15.07 ± 16.60) and in Tumor
tissues (mean = 190.57 ± 77.65). Actual percentage of methylation values are listed in the table for tumor (T), adjacent normal (N), and control
(Ctrl). B, Cumulative methylation of target genes by QM-MSP of DNA tissue samples from CRC patients. Mean cumulative methylation in stage
I / II and in stage III / IV are shown. Differences between tumor stages were not significant (P > 0.09, Student-test). Plotted is the mean (± SD; bars)
amount of cumulative methylation in Stages I / II (mean = 156.74 ± 83.96) versus Stages III / IV (mean = 213.14 ± 68.66).
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(e.g. Se about 90%) and high Sp (e.g. Sp about 90% or Sp
about 95%). So, pooling the two series (Figure 4C), we
obtain sensitivity/specificity figures of, respectively,
87%/80%, 78%/90% and 59%/95% (Table 3), and NPV/PPV
figures of 97%/47%, 95%/61% and 92%/70% (as computed
without factoring the prevalence, since the population is
already symptomatic). No significant relationship could
be identified between serum CMI rates and TNM staging
(Additional file 6: Figure S3).QM-MSP test in the sera for testing other cancers
To assess the specific relevance of our gene panel to CRC
we assayed in the same way forty seven serum samples
from patients with cancers other than CRC obtaining
sensitivity/specificity values of, e.g., 89%/25%, 43%/80%
and 28%/91% (Figure 3D).Discussion
Here, we have shown that methylation profiling based
on beadchip arrays is an effective method for selecting the
genes with promoter methylation (i.e. NPY and PENK).
Using our QM-MSP, we found a significant difference in
the methylation levels of NPY, PENK, and WIF1 betweenCRC and normal tissue and sera. On serum, the test
performs CRC detection with sensitivity/specificity values
of 87%/80% (higher sensitivity) or 78%/90%, and 59%/95%
(higher specificity).
Epigenetic abnormalities leading to gene silencing, are
a common occurrence in many malignancies [32]. They
can be considered as a way to modulate gene activity,
alternative or complementary way to gene mutations.
The Wnt signaling pathway is critical for the regulation
of colonic crypt renewal and homeostasis [33].The
deregulation of crypt homeostasis, together with the loss
of APC function by mutations, is known to initiate
colorectal carcinogenesis [34,35]. In the epigenetic field, a
large number of studies have suggested that promoter
methylation-induced silencing of Wnt pathway antagonist
genes constitute an “epigenetic gatekeeper”, leading to
constitutive Wnt signaling in many cancers [36] and
colorectal cancer [37,38] with many CpG islands re-
portedly affected in both tumors and in pre-cancerous
lesions [39].
We have focused on the Wnt antagonist gene WIF1
(Wnt inhibitor factor 1) because it has been reported
that the epigenetic silencing of this gene induces an
aberrant activation of the Wnt signaling pathway in many
cancers. This gene encodes a secreted Wnt antagonist
Figure 4 ROC curve relative to the cumulative methylation index. Sum of three (WIF1, NPY, PENK) methylation indexes are used to establish
ROC curves corresponding to Series 1 (A), Series 2 (B), total of both series (C) for CRC and Series 3 (D) for other cancers.
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activities, limiting carcinogenesis in human [19,20]. Loss
of WIF1 expression leads to aberrantly activate Wnt
signaling, which is associated with cancer and could act
as a tumor suppressor gene [21,22]. WIF1 expression was
found to be frequently down-regulated in hepatocellular
carcinoma; this down-regulation could be attributed to
hypermethylation of the WIF1 promoter [23]. In osteosar-
comas, silencing of WIF1 by promoter hypermethylation
was associated with loss of differentiation and increased
proliferation [24]. Recent studies demonstrate that the
WIF1 gene is down-regulated or silenced in astrocytomas
[25], the most common tumors of the central nervous
system, and in cervical cancer [26], both by aberrant
promoter methylation. WIF1 was reported as frequent
target of epigenetic inactivation in several tumors such
as lung, prostate, breast, bladder cancers [27-29]. In
glioblastomas, WIF1 silencing is mediated by genomic
deletion, promoter methylation, or both [30]. The WIF1
gene promoter hypermethylation has been reported incirculating DNA isolated from plasma of colorectal
adenoma and CRC patients [31].
We presumed that WIF1 could be considered as a
target for epigenetic silencing in CRC. Our results from
tissues and effluents were consistent with this hypothesis.
However, WIF1 alone could not be considered as a unique
marker for cancer detection, from effluents, although its
discriminative value in tissues was very high. This is
the reason why we investigated a larger panel including
various other genes. Accordingly, we used Illumina
methylated microarray as a genome-wide screening tool
for finding hypermethylated genes in CRC and normal
colonoscopy patients’ effluents and characterized a panel
of less than ten genes including NPY and PENK, which are
known to be involved in gastrointestinal tract functions
particularly in nutriment uptake and absorptions.
Neuropeptide Y (NPY), a neurotransmitter, acts on the
central nervous system as a potent appetite stimulator
controlled by the feedback action of both leptin from
adipose tissue and ghrelin from the stomach [40,41]. These
Table 3 Cumulative promoter hypermethylation of WIF1,
PENK, and NPY DNA in serum
CMI Specificity Sensitivity












Sensitivity (Se) and Specificity (Sp) are shown at several CMI thresholds for
both CRC series: Se > 90% (CMI = 0.62 for Series 1 and 0.01 for Series 2), Sp >
90% (1.15 and 0.94) and Sp > 95% (2.85 and 2.48). We note the existence of
two similar numerical ranges for the thresholds (0.68-0.75 for Series 1 and
0.60-0.73 for Series 2) where both Sp and Se are high (>80%). CMI values are
the cumulative methylation index of three genes.
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syndrome, two conditions clearly increasing the risk of
cancers particularly the colon cancer [42]. NPY is involved
in cell motion and cell proliferation as well as neuropep-
tide hormone activity [43]. NPY can reduce the invasive
potential of colon cancer cells in vitro [44]. In prostate
cancer, the decrease of NPY expression is associated with
aggressive clinical behavior [45]. In other studies, NPY
was shown to be frequently hypermethylated in neuro-
blastomas [46], hepatocellular carcinoma tissues [47] and
their promoter hypermethylation was correlated with in-
activation of gene expression. More recently, DeMorrow
and colleagues have demonstrated that the treatment of
cholangiocarcinoma cells with NPY as well as in vitro and
in vivo decreases both proliferation and migration [48].
The present study reports the evidence of NPY gene
involvement in CRC. Although further investigations
are required to understand whether hypermethylation
is a cause or a consequence of carcinogenesis, it is sug-
gested here to use hypermethylated gene as a blood-based
marker.
Proenkephalin (PENK), was originally shown to be
expressed in the mature nervous and neuroendocrine
systems through opioid pathway, in the regulation of
cell death and survival [49]. PENK protein has been
shown to act as apoptotic activator particularly under
chemotherapy drugs in colon cancer [50,51]. Its expres-
sion being down-regulated by Fos and Jun, two proto-
oncogenes [52]. PENK was reported to be down-regulated
in prostate cancer [53]. PENK is frequently methylated in
bladder [54], and pancreatic cancer [55-57]. Although, nostudy has so far established a direct link between the
PENK promoter hypermethylation and the development
of CRC, our findings suggest that this gene is frequently
hypermethylated in CRC patients’ effluents and might be a
valuable biomarker for its detection.
Main advantages of our QM-MSP are an analysis of
several gene performed in a single process and a quantifi-
cation of methylation allowing optimal balancing between
sensitivity and specificity. Our clinical study shows that
the variation of methylation threshold could offer of tests
for diagnosis as well as surveillance of recurrences of CRC.
For example, a CMI threshold of 0.05 appears to be more
appropriate for diagnosis/monitoring purposes, yielding
high sensitivity, detecting the real cancers; a CMI of 2 sets
our selection in the higher range of specificity, so limiting
the number of unnecessary colonoscopies. We also showed
relevance of our gene panel for detecting non colon
cancers in a series of 47 patients’ samples, where we
obtained sensitivity/specificity of, e.g., 89%/25%, 43%/80%
and 28%/91%. However, a limitation of the proposed
test is the low rate of adenomatous detection, making it ne-
cessary to establish the optimal periodicity for performing
the test.
Conclusions
In this paper we show data indicating that combining the
methylation values of NPY, PENK, and WIF1 is potentially
useful as a sensitive and specific blood test for identifying
among individuals with digestive symptoms, those in-
dividuals for whom colonoscopy is recommended. This
test, if validated, could be proposed as a cost effective
non invasive screening tool for the selection of asymp-
tomatic cancer patients for colonoscopy. The results for
other cancers suggest a possible second use for the test
for patients who would be positives to the test and
negative to colonoscopy, indicating that might undergo
other cancer-specific examinations.
Additional files
Additional file 1: Table S1. Full clinical characteristics in tumor tissue
samples and detection K-ras mutations. Mutation screening of the exon 1
of the K-ras gene containing hot spot codons 12 and 13 was assessed
from paraffin-embedded tissue blocks of 15 patients diagnosed with colon
adenocarcinoma. A short fragment of 80 bp of KRAS gene overlapping the
codon 12 and 13 was amplified and then sequenced using the following
primer pair: forward, 5’-AGGCCTGCTGAAAATGACTGAATAT-3’ and reverse,
5’-GCTGTATCGTCAAGGCACTCTT-3’. PCR was performed in a reaction volume
of 20 μL consisting of 2 μL of 10 ng/μL of DNA sample, 10 μL of 2 X
SyberGreen PCR Master Mix (Applied Biosystems), 0.80 μl of 10 μM of
forward and reverse primers (400 nmol/L in final concentration) and 6.4 μL
of sterile water. Amplifications were performed in duplicate in 96-well plates in
a real-time 7900 HT (Applied Biosystems) with as a first step a denaturating at
95 °C for 15 min, then 15 sec at 95 °C, 1 min at 60 °C for 48 cycles. Products
were purified and then sequenced in both directions (forward and reverse)
using BigDye Terminator Cycle Sequencing kit (Applied Biosystems) according
to the manufacturer’s instructions. The primers used for the sequencing were
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http://www.biomedcentral.com/1471-2407/13/566identical to those used for the PCR. The sequence reactions were run and
analyzed on an ABI 3100 Genetic Analyzer (Applied Biosystems).
Additional file 2: Table S2. Oligonucleotides.
Additional file 3: Figure S1. Selection of candidate biomarkers by DNA
methylation-array. Left: Venn diagram. Urine, Serum and Tissue lists
obtained by taking the top decile in the ranked Ca-N lists. Right: Loci
Illumina goldengate IDs.
Additional file 4: Figure S2. The bisulfite sequence of the WIF1
promoter. Representative bisulfite sequencing electrophoregram of the
WIF1 promoter verifies methylation status assessed by QS-MSP from
carcinoma colorectal (Tumor) and adjacent normal tissues (Adj Norm).
The diagram above illustrates one of the 15 samples of tumor tissues;
cytosine nucleotides underlined in black remain unchanged indicating all
sites are methylated in the amplicon product. By contrast, in the homologous
normal tissue, only thymidine nucleotides underlined in red are detected
instead of cytosine residues due to bisulfite modified DNA which is indicative
of unmethylated amplicon products. It is interesting to note that comparison
of two sequences of normal and tumoral tissues indicates that all cytosine
at non-CpG sites are converted to thymine resulting entirely from DNA
modification. This follows after sodium bisulfite treatment when referring
to the wild-type WIF1 gene sequence.
Additional file 5: Table S3. Gene promoter analysis in adjacent normal
and tumor tissues. Optimal threshold values obtained for simple gene
and in combination of 3 genes. Taking into account the different degrees
of methylation, we set threshold of CMI at 58% to obtain the highest
performance in terms of sensitivity and specificity.
Additional file 6: Figure S3. Methylation correlated in stages of CRC.
Mean cumulative methylation in I / II and III / IV stages of CRC serum
samples. Differences between both stages were not significant (P > 0.1,
Student-test). Plotted is the mean (± SD; bars) amount of cumulative
methylation in I / II stages with mean = 44.40 ± 78.53, versus in III / IV
stages with mean = 33.55 ± 61.71.
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